financetom
Business
financetom
/
Business
/
Update: MongoDB Q3 Non-GAAP Earnings, Revenue Increase; Raises Fiscal 2025 Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: MongoDB Q3 Non-GAAP Earnings, Revenue Increase; Raises Fiscal 2025 Outlook
Dec 10, 2024 2:35 AM

05:19 AM EST, 12/10/2024 (MT Newswires) -- (Updates with the stock move in the last paragraph.)

MongoDB ( MDB ) reported Q3 non-GAAP earnings late Monday of $1.16 per diluted share, up from $0.96 a year earlier.

Analysts polled by FactSet expected $0.68.

Revenue for the quarter ended Oct. 31 was $529.4 million, up from $432.9 million a year earlier.

Analysts surveyed by FactSet expected $497.2 million.

The company expects Q4 non-GAAP EPS of $0.62 to $0.65 and revenue between $515 million and $519 million. Analysts polled by FactSet expect $0.56 and $507.8 million, respectively.

The company expects fiscal 2025 non-GAAP EPS between $3.01 and $3.03 and revenue between $1.97 billion and $1.98 billion. The company previously expected non-GAAP EPS of $2.33 to $2.47 and revenue of $1.92 billion to $1.93 billion. Analysts surveyed by FactSet expect non-GAAP EPS of $2.43 and revenue of $1.94 billion.

MongoDB ( MDB ) also said Chief Operating Officer and Chief Financial Officer Michael Gordon will be stepping down on Jan. 31, 2025. The company said it has launched a search process for a new CFO, and Serge Tanjga, senior vice president of finance, will be interim CFO starting Feb. 1 if a permanent successor hasn't been named by then.

Shares of the company were down more than 3% in recent premarket activity Tuesday, giving up a gain of 8.5% in after-hours activity on Monday.

Price: 336.50, Change: -13.63, Percent Change: -3.89

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Credo Technology Group Holding Insider Sold Shares Worth $11,711,533, According to a Recent SEC Filing
Credo Technology Group Holding Insider Sold Shares Worth $11,711,533, According to a Recent SEC Filing
Oct 10, 2024
03:05 AM EDT, 10/08/2024 (MT Newswires) -- Lip Bu Tan, Director, on October 03, 2024, sold 368,046 shares in Credo Technology Group Holding ( CRDO ) for $11,711,533. Following the Form 4 filing with the SEC, Tan has control over a total of 2,493,164 shares of the company, with 49,166 shares held directly and 2,443,998 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1807794/000162828024042449/xslF345X05/wk-form4_1728345201.xml...
Calian Group up 4.5% as It Secures New Contracts for its Nuclear Division in Q4
Calian Group up 4.5% as It Secures New Contracts for its Nuclear Division in Q4
Oct 10, 2024
01:34 PM EDT, 10/08/2024 (MT Newswires) -- Calian Group ( CLNFF ) shares were last seen up 4.5% higher after the company on Tuesday said it secured a number of new contracts in its fiscal fourth quarter for its nuclear and environmental services division. The company said the new contracts, 19 in total, are a 58% increase over the third...
Patrick Industries Prices $500 Million Private Placement of Notes
Patrick Industries Prices $500 Million Private Placement of Notes
Oct 10, 2024
03:13 AM EDT, 10/08/2024 (MT Newswires) -- Patrick Industries ( PATK ) said late Monday it priced a private placement of $500 million principal amount of 6.375% senior notes due 2032. Net proceeds will be used to fund the redemption of $300 million aggregate amount of 7.5% senior notes due 2027, other debt repayments and other related fees and expenses,...
Zealand, Boehringer win FDA breakthrough status to treat fatty liver
Zealand, Boehringer win FDA breakthrough status to treat fatty liver
Oct 10, 2024
FRANKFURT, Oct 8 (Reuters) - Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's Breakthrough Therapy for the review of their experimental weight-loss drug for the treatment of a type of fatty liver disease. The companies said in a statement that the FDA's speedier review will be for the use of drug candidate...
Copyright 2023-2026 - www.financetom.com All Rights Reserved